Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT07421284
What this trial is testing

Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy

Who this might be right for
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 900
Large-scale testing (Phase 3)Not Yet RecruitingNCT07474649
What this trial is testing

Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

Who this might be right for
Coronary AtherosclerosisMixed DyslipidemiaHypercholesterolemia
Daiichi Sankyo 103
Testing effectiveness (Phase 2)Study completedNCT07421232
What this trial is testing

Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

Who this might be right for
Hypercholesterolemia and Mixed Hyperlipidemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 156
Large-scale testing (Phase 3)Looking for participantsNCT07614958
What this trial is testing

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

Who this might be right for
Mixed DyslipidemiaHypercholesterolaemia
A. Menarini International Licensing S.A. 426
Large-scale testing (Phase 3)Study completedNCT04885218
What this trial is testing

Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

Who this might be right for
Non-familial HypercholesterolemiaMixed Hyperlipidemia
Jiangsu HengRui Medicine Co., Ltd. 692
Large-scale testing (Phase 3)Looking for participantsNCT07421297
What this trial is testing

Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia

Who this might be right for
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 760
Large-scale testing (Phase 3)Not Yet RecruitingNCT07444086
What this trial is testing

QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia

Who this might be right for
Primary Hypercholesterolemia or Mixed Hyperlipidemia
Qilu Pharmaceutical Co., Ltd. 510
Large-scale testing (Phase 3)Looking for participantsNCT07473960
What this trial is testing

IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

Who this might be right for
Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Innovent Biologics (Suzhou) Co. Ltd. 198